Literature DB >> 17721938

Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies.

Roxana M Ionescu1, Josef Vlasak, Colleen Price, Marc Kirchmeier.   

Abstract

Temperature-induced unfolding of three humanized IgG1 monoclonal antibodies and their Fab and Fc fragments was monitored by differential scanning calorimetry at neutral pH. With some exceptions, the thermogram of the intact antibody presents two peaks and the transition with the larger experimental enthalpy contains the contribution from the Fab fragments. Although the measured enthalpy was similar for all three Fab fragments studied, the apparent melting temperatures were found to vary significantly, even for Fab fragments originating from the same human germline. Therefore, we propose to use the measured enthalpy of unfolding as the key parameter to recognize the unfolding events in the melting profile of an intact IgG1 antibody. If the variable domain sequences, resulting from complementarity determining regions (CDRs) grafting and humanization, destabilize the Fab fragment with respect to the CH3 domain, the first transition represents the unfolding of the Fab fragment and the CH2 domain, while the second transition represents CH3 domain unfolding. Otherwise, the first transition represents CH2 domain unfolding, and the second transition represents the unfolding of the Fab fragment and the CH3 domain. In some cases, the DSC profile may present three transitions, with the Fab unfolding occurring at distinct temperatures compared to the melting of the CH2 and CH3 domains. If the DSC profile of a humanized IgG1 monoclonal antibody cannot be described by the model above, the result may be an indication of significant structural heterogeneity and/or of disruption of the Fab cooperative unfolding. Low stability or heterogeneity of the Fab fragment may prove problematic for long-term storage or consistency of production. Therefore, understanding the features of a DSC profile is important for clone selection and process maturation in the early stages of development of therapeutic monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17721938     DOI: 10.1002/jps.21104

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  85 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.

Authors:  James T Heads; Ralph Adams; Lena E D'Hooghe; Matt J T Page; David P Humphreys; Andrew G Popplewell; Alastair D Lawson; Alistair J Henry
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

3.  Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.

Authors:  Haixia Wu; Kristopher Truncali; Julie Ritchie; Rachel Kroe-Barrett; Sanjaya Singh; Anne S Robinson; Christopher J Roberts
Journal:  MAbs       Date:  2015-08-12       Impact factor: 5.857

4.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

5.  Insights into protein-polysorbate interactions analysed by means of isothermal titration and differential scanning calorimetry.

Authors:  Claudia Hoffmann; Alfred Blume; Inge Miller; Patrick Garidel
Journal:  Eur Biophys J       Date:  2009-02-03       Impact factor: 1.733

6.  Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Authors:  Takahiko Ito; Kouhei Tsumoto
Journal:  Protein Sci       Date:  2013-09-30       Impact factor: 6.725

7.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

8.  Temperature stability of proteins: Analysis of irreversible denaturation using isothermal calorimetry.

Authors:  Arne Schön; Benjamin R Clarkson; Maria Jaime; Ernesto Freire
Journal:  Proteins       Date:  2017-08-08

9.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

10.  Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry.

Authors:  Jianxin Guo; Sandeep Kumar; Amarnauth Prashad; Jason Starkey; Satish K Singh
Journal:  Pharm Res       Date:  2014-01-24       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.